scholarly journals Promoter methylation patterns of ABCB1, ABCC1 and ABCG2 in human cancer cell lines, multidrug-resistant cell models and tumor, tumor-adjacent and tumor-distant tissues from breast cancer patients

Oncotarget ◽  
2016 ◽  
Vol 7 (45) ◽  
pp. 73347-73369 ◽  
Author(s):  
Melanie Spitzwieser ◽  
Christine Pirker ◽  
Bettina Koblmüller ◽  
Georg Pfeiler ◽  
Stefan Hacker ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Cancer Patients ◽  
Human Cancer ◽  
Multidrug Resistant ◽  
Resistant Cell ◽  
Human Cancer Cell ◽  
Cell Models ◽  
Breast Cancer Patients ◽  
Human Cancer Cell Lines ◽  
Methylation Patterns

Design, Synthesis and Biological Evaluation of 3-(3,4,5-Trimethoxyphenyl)- 5-(2-(5-arylbenzo[b]thiophen-3-yl)oxazol-5-yl)isoxazole Derivatives as Anticancer Agents

2020 ◽  
Vol 17 (5) ◽  
pp. 345-351
Author(s):  
Syndla Premalatha ◽  
G. Rambabu ◽  
Islavathu Hatti ◽  
Dittakavi Ramachandran
Keyword(s):  
Breast Cancer ◽  
Anticancer Activity ◽  
Cell Lines ◽  
Cancer Cell ◽  
Human Cancer ◽  
Cancer Cell Lines ◽  
Biological Evaluation ◽  
Human Cancer Cell ◽  
Human Cancer Cell Lines ◽  
Isoxazole Derivatives

A new series of 3-(3,4,5-trimethoxyphenyl)-5-(2-(5-arylbenzo[b]thiophen-3-yl)oxa zol-5- yl)isoxazole derivatives were designed and synthesized. All these derivatives were evaluated for their anticancer activity against various human cancer cell lines such as MCF-7 (breast cancer), A549 (lung cancer), DU-145 (prostate cancer) and MDA MB-231 (breast cancer)-four human cancer cell lines by using MTT assay. Here, etoposide was used as a standard reference drug and most of the compounds were exhibited good anticancer activity with respect to cell lines. Among all compounds, five compounds 11b, 11c, 11f, 11i and 11j showed more potent activity than standard drug, in which, compound 11f was the most promising compound.

scholarly journals Antiestrogen-resistant human breast cancer cells require activated Protein Kinase B/Akt for growth

2005 ◽  
Vol 12 (3) ◽  
pp. 599-614 ◽  
Author(s):  
T Frogne ◽  
J S Jepsen ◽  
S S Larsen ◽  
C K Fog ◽  
B L Brockdorff ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Cancer Patients ◽  
Cell Lines ◽  
Human Breast Cancer ◽  
Neutralizing Antibodies ◽  
Breast Cancer Cells ◽  
Resistant Cell ◽  
Breast Cancer Patients ◽  
Human Breast ◽  
Mcf 7

Development of acquired resistance to antiestrogens is a major clinical problem in endocrine treatment of breast cancer patients. The IGF system plays a profound role in many cancer types, including breast cancer. Thus, overexpression and/or constitutive activation of the IGF-I receptor (IGF-IR) or different components of the IGF-IR signaling pathway have been reported to render breast cancer cells less estrogen dependent and capable of sustaining cell proliferation in the presence of antiestrogens. In this study, growth of the antiestrogen-sensitive human breast cancer cell line MCF-7 was inhibited by treatment with IGF-IR-neutralizing antibodies. In contrast, IGF-IR-neutralizing antibodies had no effect on growth of two different antiestrogen-resistant MCF-7 sublines. A panel of antiestrogen-resistant cell lines was investigated for expression of IGF-IR and either undetectable or severely reduced IGF-IR levels were observed. No increase in insulin receptor substrate 1 (IRS-1) or total PKB/Akt (Akt) was detected in the resistant cell lines. However, a significant increase in phosphorylated Akt (pAkt) was found in four of six antiestrogen-resistant cell lines. Overexpression of pAkt was associated with increased Akt kinase activity in both a tamoxifen- and an ICI 182,780-resistant cell line. Inhibition of Akt phosphorylation by the phosphatidylinositol 3-kinase (PI3-K) inhibitor wortmannin or the Akt inhibitor SH-6 (structurally modified phosphatidyl inositol ether liquid analog PIA 6) resulted in a more pronounced growth inhibitory effect on the antiestrogen-resistant cells compared with the parental cells, suggesting that signaling via Akt is required for antiestrogen-resistant cell growth in at least a subset of our antiestrogen-resistant cell lines. PTEN expression and activity was not decreased in cell lines overexpressing pAkt. Our data demonstrate that Akt is a target for treatment of antiestrogen-resistant breast cancer cell lines and we suggest that antiestrogen-resistant breast cancer patients may benefit from treatment targeted to inhibit Akt signaling.

Effect of the Method of Preparation on the Composition and Cytotoxic Activity of the Essential Oil of Pituranthos tortuosus

2011 ◽  
Vol 66 (3-4) ◽  
pp. 143-148 ◽  
Author(s):  
Hossam M. Abdallah ◽  
Shahira M. Ezzat
Keyword(s):  
Breast Cancer ◽  
Essential Oil ◽  
Cell Line ◽  
Cell Lines ◽  
Cancer Cell ◽  
Human Cancer ◽  
Cancer Cell Line ◽  
Cancer Cell Lines ◽  
Human Cancer Cell ◽  
Human Cancer Cell Lines

The aerial parts of Pituranthos tortuosus (Desf.) Benth and Hook (Apiaceae), growing wild in Egypt, yielded 0.8%, 0.6%, and 1.5% (v/w) of essential oil when prepared by hydrodistillation (HD), simultaneous hydrodistillation-solvent (n-pentane) extraction (Lickens- Nickerson, DE), and conventional volatile solvent extraction (preparation of the “absolute”, SE), respectively. GC-MS analysis showed that the major components in the HD sample were β-myrcene (18.81%), sabinene (18.49%), trans-iso-elemicin (12.90%), and terpinen- 4-ol (8.09%); those predominent in the DE sample were terpinen-4-ol (29.65%), sabinene (7.38%), γ-terpinene (7.27%), and β-myrcene (5.53%); while the prominent ones in the SE sample were terpinen-4-ol (15.40%), dill apiol (7.90%), and allo-ocimene (4E,6Z) (6.00%). The oil prepared in each case was tested for its cytotoxic activity on three human cancer cell lines, i.e. liver cancer cell line (HEPG2), colon cancer cell line (HCT116), and breast cancer cell line (MCF7). The DE sample showed the most potent activity against the three human cancer cell lines (with IC50 values of 1.67, 1.34, and 3.38 μg/ml against the liver, colon, and breast cancer cell lines, respectively). Terpinen-4-ol, sabinene, γ-terpinene, and β-myrcene were isolated from the DE sample and subjected to a similar evaluation of cytotoxic potency; signifi cant activity was observed

scholarly journals Co-enzyme Q10, riboflavin and niacin supplementation on alteration of DNA repair enzyme and DNA methylation in breast cancer patients undergoing tamoxifen therapy

2008 ◽  
Vol 100 (6) ◽  
pp. 1179-1182 ◽  
Author(s):  
Vummidi Giridhar Premkumar ◽  
Srinivasan Yuvaraj ◽  
Palanivel Shanthi ◽  
Panchanatham Sachdanandam
Keyword(s):  
Breast Cancer ◽  
Dna Methylation ◽  
Dna Repair ◽  
Cancer Patients ◽  
Good Prognosis ◽  
Breast Cancer Patients ◽  
Repair Enzymes ◽  
Methylation Patterns ◽  
To Receive ◽  
Supplement Therapy

In the present study, eighty-four breast cancer patients were randomized to receive a daily supplement of 100 mg co-enzyme Q10, 10 mg riboflavin and 50 mg niacin (CoRN), one dosage per d along with 10 mg tamoxifen twice per d. A significant increase in poly(ADP-ribose) polymerase levels and disappearance of RASSF1A DNA methylation patterns were found in patients treated with supplement therapy along with tamoxifen compared to untreated breast cancer patients and tamoxifen alone-treated patients. An increase in DNA repair enzymes and disappearance of DNA methylation patterns attributes to reduction in tumour burden and may suggest good prognosis and efficacy of the treatment.

Complement - dependent Serum Cytotoxicity of Cancer Patients Studied by 51Cr Release Assay on Human Cancer Lines

1977 ◽  
Vol 63 (1) ◽  
pp. 97-107 ◽  
Author(s):  
José Garcia Puche ◽  
Silvana Canevari ◽  
Giuseppe Fossati ◽  
Giuseppe Della Porta ◽  
Paolo Vezzoni
Keyword(s):  
Breast Cancer ◽  
Lymph Node ◽  
Cancer Patients ◽  
Lymph Node Metastases ◽  
Human Cancer ◽  
Cancer Tissue ◽  
Breast Cancer Patients ◽  
Cancer Line ◽  
Release Assay ◽  
Node Metastases

The conditions for a 51Cr release assay on cell lines derived from human solid tumors were determined by using a rabbit antihuman antiserum with human AB serum as source of complement. By this assay 38 sera collected before and after surgery from 19 breast cancer patients and 28 sera from 12 melanoma patients and 16 healthy donors were tested on 3 lines derived from breast cancer tissue and 1 line derived from normal breast tissue. Ten of the breast cancer patients had lymph node metastases and 9 did not. Positive reactions were obtained from 4 breast cancer patients, all with lymph node metastases, and from 1 healthy donor. In a second experiment, 58 coded sera belonging to 4 different groups of cancer and non-cancer individuals were assayed on a colonic cancer line (HT-29), and 33 and 20 of them were also tested on a melanoma line (MeWo) and on a breast cancer line (MaCa 13), respectively. Positive responses were few, and were more frequently observed among transfused than non-transfused patients.

scholarly journals Methylation patterns in cell-free plasma DNA reflect removal of the primary tumor and drug treatment of breast cancer patients

2010 ◽  
Vol 128 (2) ◽  
pp. 492-499 ◽  
Author(s):  
Thomas E. Liggett ◽  
Anatoliy A. Melnikov ◽  
Jeffrey R. Marks ◽  
Victor V. Levenson
Keyword(s):  
Breast Cancer ◽  
Drug Treatment ◽  
Cancer Patients ◽  
Primary Tumor ◽  
Breast Cancer Patients ◽  
Plasma Dna ◽  
Methylation Patterns ◽  
Free Plasma

scholarly journals Meta-analysis of the clinicopathological significance of miRNA-145 in breast cancer

2020 ◽  
Vol 40 (9) ◽  
Author(s):  
Peng Lv ◽  
Zhenzhu Zhang ◽  
Li Hou ◽  
Yayue Zhang ◽  
Lingeng Lu ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Tumor Suppressor ◽  
Cancer Patients ◽  
Human Cancer ◽  
Meta Analysis ◽  
Normal Breast ◽  
Breast Cancer Patients ◽  
Normal Tissues ◽  
Cancer Tissues ◽  
Low Expression

Abstract Low expression of tumor suppressor microRNA (miRNA) and high expression of carcinogenic miRNA promote the occurrence and progression of human cancer. Most studies show that miR-145 is a tumor suppressor miRNA, and is closely related to the clinicopathology of breast cancer. However, the results are still inconsistent. Therefore, we conducted a meta-analysis on the basis of eligible studies to summarize the possible correlation between miR-145 and the clinicopathology and prognosis of breast cancer. Using PubMed, Embase, Web of Science, Wanfang and CNKI, we searched all published papers written in either English or Chinese on miR-145 expression in breast cancer from 1990 to November 2019 for meta-analysis. We used standardized mean difference (SMD) to evaluate the differential expression of miR-145 in breast cancer tissues and adjacent normal tissues or normal breast tissues. We found that miR-145 expression was significantly lower in breast cancer tissues than that in adjacent normal tissues (SMD = −2.93, P<0.0001) and in healthy women (SMD = −0.52, P=0.009). miR-145 expression was lower in breast cancer patients with ER-positive (SMD = 0.65, P<0.001), HER-2-positive (SMD = −1.04, P<0.001), compared with their counterparts, respectively. In addition, breast cancer patients with low expression of miR-145 had larger tumor diameters (SMD = −1.97, P<0.001) and lymph node metastasis (SMD = −1.75, P<0.001) that are unfavorable prognostic factors. Conclusion: Low miR-145 is observed in breast cancer, which is closely related to molecular subtypes and unfavorable factors of breast cancer. These findings indicate that miR-145 is tumor suppressor miRNA, and may be a potential diagnostic and prognostic marker in breast cancer.

Design, Synthesis and Anticancer Evaluation of 1,2,4-Oxadiazole Bearing Isoxazole-Pyrazole Derivatives

2020 ◽  
Vol 17 (5) ◽  
pp. 352-359 ◽  
Author(s):  
Bhukya Ravinaik ◽  
Dittakavi Ramachandran ◽  
Mandava Venkata Basaveswara Rao
Keyword(s):  
Breast Cancer ◽  
Cell Lines ◽  
Human Cancer ◽  
Pyrazole Derivatives ◽  
Human Cancer Cell ◽  
Design Synthesis ◽  
Standard Drug ◽  
Human Cancer Cell Lines ◽  
A549 Lung ◽  
Mcf 7

A novel library of 1,2,4-oxadiazole bearing isoxazole-pyrazole derivatives (13a-j) were designed, synthesized and evaluated for their anticancer activity towards MCF-7 (breast cancer), A549 (lung cancer), DU-145 (prostate cancer) and MDA MB-231 (breast cancer) human cancer cell lines by MTT assay. Here etoposide used as standard drug. Among them, five compounds (13b, 13c, 13d, 13h and 13i) were exhibited more potent activity. In which compound 13h was the most promising compound against all cell lines MCF-7, A549, DU-145 and MDA MB-231.

scholarly journals Synthesis and potential cytotoxic activity of some new benzoxazoles, imidazoles, benzimidazoles and tetrazoles

2013 ◽  
Vol 63 (2) ◽  
pp. 253-264 ◽  
Author(s):  
Subramaniyan Arulmurugan ◽  
Helen P. Kavitha
Keyword(s):  
Breast Cancer ◽  
Mass Spectrometry ◽  
Colon Cancer ◽  
Heterocyclic Compounds ◽  
Human Cancer ◽  
Assay Method ◽  
Human Cancer Cell ◽  
Human Cancer Cell Lines ◽  
Ht 29 ◽  
Mcf 7

2 The present work deals with the synthesis of some novel heterocyclic compounds such as benzoxazoles , 7, 13 and 19, imidazoles 3, 8, 14 and 20, benzimidazoles 4, 9, 15 and 21, and tetrazoles 10, 16, and 22. The synthesized compounds were characterized by IR, 1H NMR, mass spectrometry and elemental analysis. The compounds were evaluated for cytotoxicity against human cancer cell lines such as MCF-7 (breast cancer) and HT-29 (colon cancer) by the MTT assay method. Among the tested compounds, 4,4’-sulfonylbis(N-(2-(1H-benzo[d]imidazol- -2-yl)ethyl)aniline (9), N-bis(2-(benzo[d]oxazol-2-yl)-ethyl)- 6-phenyl-1,3,5-triazine-2,4-diamine (13), N-bis(2-(1H-benzo[ d]imidazol-2-yl)ethyl)-6-phenyl-1,3,5-triazine-2,4-diamine (15) and N-tris(2-1H-benzo[d]imidazol-2-yl)ethyl)- 1,3,5-triazine-2,4,6-triamine (21) showed potent cytotoxicity.

Sign in / Sign up

Export Citation Format

Share Document